NuCana plc American Depositary Share
NCNA Real Time Price USDRecent trades of NCNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by NCNA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
NCNA Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Synthesis of phosphate derivatives Aug. 06, 2024
-
Patent Title: 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds Aug. 06, 2024
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer Mar. 12, 2024
-
Patent Title: Synthesis of 3′-deoxyadenosine-5′-o-[phenyl(benzyloxy-l-alaninyl)]phosphate (nuc-738) Feb. 13, 2024
-
Patent Title: Formulations of phosphoramidate derivatives of nucleoside drugs Oct. 17, 2023
-
Patent Title: Formulation comprising a gemcitabine-prodrug Jul. 25, 2023
-
Patent Title: Gemcitabine prodrugs Apr. 18, 2023
-
Patent Title: Diastereoselective synthesis of phosphate derivatives Mar. 14, 2023
-
Patent Title: Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds Jan. 24, 2023
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer Jan. 24, 2023
-
Patent Title: Synthesis of phosphate derivatives Aug. 16, 2022
-
Patent Title: Floxuridine synthesis Aug. 16, 2022
-
Patent Title: Cancer treatments Aug. 02, 2022
-
Patent Title: Crystalline form of gemcitabine Jul. 05, 2022
-
Patent Title: 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds Jun. 07, 2022
-
Patent Title: Process for preparing nucleoside prodrugs Jun. 22, 2021
-
Patent Title: Formulation comprising a gemcitabine-prodrug Jun. 22, 2021
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer May. 04, 2021
-
Patent Title: Phosphoramidate nucleoside derivatives as anticancer agents Feb. 02, 2021
-
Patent Title: Formulation comprising a gemcitabine-prodrug Sep. 29, 2020
-
Patent Title: Methods of separating gemcitabine-phosphate diastereoisomers Jun. 02, 2020
-
Patent Title: Gemcitabine prodrugs May. 26, 2020
-
Patent Title: Combination therapy for cancer May. 26, 2020
-
Patent Title: 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds Feb. 25, 2020
-
Patent Title: Phosphoramidate compounds and methods of use Sep. 03, 2019
-
Patent Title: Formulation comprising a gemcitabine-prodrug Nov. 06, 2018
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer Jul. 17, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to NCNA
Number of mentions of NCNA in WallStreetBets Daily Discussion
Recent picks made for NCNA stock on CNBC
ETFs with the largest estimated holdings in NCNA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NCNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.